TherapeuticsMD Q3 net product revenue $24.5M (+41% YoY); appoints Hugh O'Dowd CEO

TherapeuticsMD, Inc.

2022-Q3 EPS reported -$16.68 revenue$68,273,000

CEO Robert Finizio to become Vice Chair; President Hugh O'Dowd becomes CEO effective on or before Dec 31, 2021.
Q3 net product revenue $24.5M, up 41% YoY; ANNOVERA TRx 8,351 (+62.7% YoY).
Net loss $47.4M ($0.11/sh) vs $32.6M ($0.12/sh) in Q3 2020; includes $7.3M severance.
Cost savings plan to cut SG&A by $40M in 2022; additional ~$20M annualized from vitaCare divestiture.
Manufacturing issues: ANNOVERA batch failures; supplemental NDA PDUFA date Dec 12, 2021; revenue covenant risk.

item 2.02 item 7.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hugh O'Dowd

Director

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-31
Filed: November 12, 2021, 6:59 PM ET

Mr. O’Dowd will also be appointed to the Company’s Board of Directors.

Role change

Hugh O'Dowd

Chief Executive Officer

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-31
Filed: November 12, 2021, 6:59 PM ET

Mr. Hugh O’Dowd, the Company’s current President, will succeed Mr. Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, as the Company’s Chief Executive Officer effective on or before December 31, 2021.

Role change

Robert G. Finizio

Vice Chair of the Board of Directors

TXMD · TherapeuticsMD, Inc.

Effective: 2021-12-31
Successor: Hugh O'Dowd
Filed: November 12, 2021, 6:59 PM ET

Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh O'Dowd was appointed as Director at TherapeuticsMD, Inc..

Action: appointed
Role: Director

Exact text from the filing

Mr. O’Dowd will also be appointed to the Company’s Board of Directors.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hugh O'Dowd was appointed as Chief Executive Officer at TherapeuticsMD, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Mr. Hugh O’Dowd, the Company’s current President, will succeed Mr. Robert G. Finizio, the Company’s Co-founder and current Chief Executive Officer, as the Company’s Chief Executive Officer effective on or before December 31, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert G. Finizio was appointed as Vice Chair of the Board of Directors at TherapeuticsMD, Inc..

Action: appointed
Role: Vice Chair of the Board of Directors

Exact text from the filing

Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors.

View on SEC.gov

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-056427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.